हिंदी में पढ़ें

Mankind Pharma

Mankind Pharma shares rise as profits jump 29% in Q2 on strong sales recovery

Mankind Pharma shares rise as profits jump 29% in Q2 on strong sales recovery

Wed, Nov 06, 2024

Mankind Pharma, one of India’s largest pharmaceutical players, witnessed its shares surge by 6 per cent to a peak of Rs 2,882.75 on the BSE after announcing a robust 29 per cent year-on-year profit growth for the quarter ending September 2024.

Mankind Pharma Q2 Results: Net profit rises 29% to Rs 659 crore; revenue up 13.6%

Mankind Pharma Q2 Results: Net profit rises 29% to Rs 659 crore; revenue up 13.6%

Tue, Nov 05, 2024

Mankind Pharma Q2 Results: Mankind Pharma on Tuesday reported a 29 per cent rise in its consolidated net profit to Rs 658.88 crore for the second quarter ended September 2024, helped by recovery in volume.

Mankind Pharma completes Rs 13,768 crore BSV acquisition

Mankind Pharma completes Rs 13,768 crore BSV acquisition

Thu, Oct 24, 2024

BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins.

TRENDING NOW

Mankind Pharma hits an all-time high after inclusion in FTSE Global Indices

Mankind Pharma hits an all-time high after inclusion in FTSE Global Indices

Mon, Nov 20, 2023

The Mankind Pharma stock hit an all-time high of 1987.85 on BSE on Monday (November 20, 2023) after the company was included in the large cap segment at the FTSE Global Indices.

Mankind Pharma Q2 Results: Net profit rises 21% to Rs 511 crore

Mankind Pharma Q2 Results: Net profit rises 21% to Rs 511 crore

Tue, Oct 31, 2023

Mankind Pharma Q2 Results: Mankind Pharma said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments.

Mankind Pharma restructures portfolio, favors Mid Cap stocks over Large Cap

Mankind Pharma restructures portfolio, favors Mid Cap stocks over Large Cap

Mon, Jul 31, 2023

ManKindPharma straight into Large Cap. Share of Large Cap decreased, Mid Cap increased. Which stocks moved from Mid to Large Cap? See full details in this video

Mankind Pharma settles flat post-Q4 announcement

Mankind Pharma settles flat post-Q4 announcement

Wed, May 31, 2023

Mankind Pharma Q4 results: The country's fourth-largest pharmaceutical company by domestic sales reported a 50 per cent year-on-year (YOY) rise in Q4 profit helped by lower input costs.

Income Tax Department Raids Mankind Pharma's Delhi Office, Watch Details Here

Income Tax Department Raids Mankind Pharma's Delhi Office, Watch Details Here

Thu, May 11, 2023

The Income Tax (I-T) department conducted searches at Mankind Pharma's New Delhi offices, as per sources. However, Zee Business has not received any response to the email it sent to the company, regarding the development.

Income Tax dept raids Mankind Pharma's offices premises over tax evasion allegations

Income Tax dept raids Mankind Pharma's offices premises over tax evasion allegations

Thu, May 11, 2023

I-T raids Mankind Pharma: The maker of Manforce condoms, Prega News pregnancy test kits and Gas-O-Fast sachets added that the investigation has had no impact on its operational performance.

Mankind Pharma IPO listing: Manforce condom maker off listing high, but remains well among India's top 100 most valuable firms

Mankind Pharma IPO listing: Manforce condom maker off listing high, but remains well among India's top 100 most valuable firms

Wed, May 10, 2023

Mankind Pharma IPO listing: Mankind Pharma — whose popular brands include Manforce and Prega News — made a blockbuster debut on stock exchanges BSE and NSE on May 9, finishing the listing day at a premium of 32 per cent over the upper end of its IPO price range.

News Par Views: After Listing At A Premium Of 20% Mankind Pharma's Management Explains Growth Plans | Anil Singhvi

News Par Views: After Listing At A Premium Of 20% Mankind Pharma's Management Explains Growth Plans | Anil Singhvi

Wed, May 10, 2023

What is the business model and future plan of Mankind Pharma? Where will the money raised from IPO be used? Know from the company's Chairman, Ramesh Juneja and VC & MD Rajeev Juneja. Watch Anil Singhvi's exclusive conversation with Mankind Pharma's Chairman, Ramesh Juneja and VC & MD Rajeev Juneja after a strong listing at a premium of 20%.

Mankind Pharma shares fall after blockbuster listing day; here's what investors should do

Mankind Pharma shares fall after blockbuster listing day; here's what investors should do

Wed, May 10, 2023

Mankind Pharma share price: The stock of Mankind Pharma — whose popular products include Manforce condoms and Prega News pregnancy test kits — succumbed to likely profit-booking on Wednesday, a day after the stock clocked a stellar debut in the secondary market. Mankind Pharma shares scaled a high of Rs 1,430 apiece on BSE and NSE each on the listing day.

Buy, sell or hold Mankind Pharma shares after stellar debut? What Anil Singhvi recommends

Buy, sell or hold Mankind Pharma shares after stellar debut? What Anil Singhvi recommends

Tue, May 09, 2023

Mankind Pharma (MANKIND) made a blockbuster debut on stock exchanges BSE and NSE on Tuesday, May 9, 2023, changing hands at levels as high as Rs 1,400 apiece. Market wizard Anil Singhvi recommends buying the stock from a long-term perspective.

Mankind Pharma IPO Listing: Bumper Debut, Shares List At 20.37% Premium Over Issue Price On BSE, NSE

Mankind Pharma IPO Listing: Bumper Debut, Shares List At 20.37% Premium Over Issue Price On BSE, NSE

Tue, May 09, 2023

Mankind Pharma shares listed at 20.37% premium over IPO price on NSE and BSE amid positive domestic market. The share debuted at Rs 1300 on the stock exchanges, as compared to the issue price of Rs 1080.

Mankind Pharma IPO Listing: BUY, SELL Or HOLD - What To Do? Details Anil Singhvi

Mankind Pharma IPO Listing: BUY, SELL Or HOLD - What To Do? Details Anil Singhvi

Tue, May 09, 2023

Shares of Mankind Pharma will be listed today. The company has fixed its issue price at Rs 1080 per share. How will be its the listing - at a discount or a premium? What should investors do after listing? Know the opinion of Anil Singhvi on Mankind Pharma's listing.

Mankind Pharma IPO Listing HIGHLIGHTS: A stellar market debut for Manforce condom maker; shares finish listing day at 32% premium

Tue, May 09, 2023

Mankind Pharma IPO listing HIGHLIGHTS: Mankind Pharma (MANKIND) shares made a strong secondary market debut on Tuesday, May 9. The strong listing of the stock of Mankind Pharma, whose popular brands include Manforce and Prega News, was even better than what Zee Business Managing Editor Anil Singhvi had predicted. The debut comes after the company's IPO to raise up to Rs 4,326 crore concluded last month with a subscription of more than 15 times. Market wizard Anil Singhvi has a long-term 'buy' call on Mankind Pharma. Catch minute-by-minute updates on the Mankind Pharma listing, the views of Zee Business Managing Editor Anil Singhvi and other experts, and much more here on Zeebiz.com's blog.

Mankind Pharma IPO - Should You Apply Or Avoid? Watch Full Analysis By Anil Singhvi

Mankind Pharma IPO - Should You Apply Or Avoid? Watch Full Analysis By Anil Singhvi

Wed, Apr 26, 2023

Today is the second day of Mankind Pharma's IPO. The company has fixed its price band at Rs 1026-1080. What is positive and what is negative in Mankind Pharma? What should long-term investors do? Should you apply or avoid this issue?? Know the opinion of Anil Singhvi.

News Par Views: What Is The Future Plan Of Mankind Pharma? Know From Company's VC & MD, Rajeev Juneja

News Par Views: What Is The Future Plan Of Mankind Pharma? Know From Company's VC & MD, Rajeev Juneja

Tue, Apr 25, 2023

What is the future plan of Mankind Pharma, how is the business model? Where will the money raised from the IPO be used? What is the growth outlook ahead? Watch Anil Singhvi's exclusive interview with Rajeev Juneja, VC & MD of Mankind Pharma.

Mankind Pharma IPO opens on April 25--Check GMP, price, other details here

Mankind Pharma IPO opens on April 25--Check GMP, price, other details here

Mon, Apr 24, 2023

Mankind Pharma is all set to launch an initial share sale on April 25. The company opened its anchor book for institutional investors on April 24. The Mankind Pharma IPO is the fourth primary market offering to hit Dalal Street in 2023 after Divgi TorqTransfer Systems, Global Surfaces and Udayshivakumar Infra.

Mankind IPO to hit the Street soon: 10 things to know

Mankind IPO to hit the Street soon: 10 things to know

Mon, Apr 24, 2023

Mankind Pharma's IPO is entirely an offer for sale (OFS) of more than four crore equity shares by existing shareholders and promoters. At the upper end of the price band, the IPO size is estimated at Rs 4,326 crore.

Mankind Pharma IPO: Subscription to Open on April 25

Mankind Pharma IPO: Subscription to Open on April 25

Tue, Apr 18, 2023

Mankind Pharma, the 4th-largest pharmaceutical company in India, is all set to launch its IPO on April 25, 2023. The issue will remain open for subscription till April 27. The initial stake sale is entirely an offer-for-sale by promoters and existing shareholders.

Mankind Pharma IPO to open on April 25

Mankind Pharma IPO to open on April 25

Tue, Apr 18, 2023

Mankind Pharma IPO: The three-day initial public offering (IPO) will conclude on April 27, and the bidding for anchor investors will open on April 24, according to the red herring prospectus (RHP).

Upcoming IPOs: 9 companies to raise Rs 17,000 crore from primary market

Upcoming IPOs: 9 companies to raise Rs 17,000 crore from primary market

Mon, Feb 27, 2023

At least 9 companies are planning to launch IPOs during the next 5-6 weeks. Several companies have already filed their Draft Red Herring Prospectus (DRHP)-- a preliminary registration document for companies looking to go public.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x